6-month INFUSE data show eptinezumab improves migraine outcomes, including headache days and patient-reported measures, even after prior CGRP failures.
Amaal Starling, MD
Advertisement
Amaal Starling, MD, is a neurologist and an Associate Professor of Neurology in the Mayo Clinic College of Medicine and Science.
Articles by Amaal Starling, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Patient Care Online
1
Zasocitinib Tops Deucravacitinib for Skin Clearance in Phase 3 Psoriasis Trial
2
FDA Clears Wave Neuroscience MeRT System for PTSD
3
AD109 Reduces OSA Severity in Phase 3 Trial of CPAP-Intolerant Adults
4
7 Late-Breaking Clinical Trials to Watch For at SLEEP 2026
5